NextCure (NXTC) Other Non-Current Assets (2018 - 2026)
NextCure (NXTC) posted quarterly Other Non-Current Assets of $847000.0 for Q1 2026, up 158.23% year-over-year from $328000.0 in Q1 2025, and up 55.13% quarter-over-quarter from $546000.0 in Q4 2025.
NextCure (NXTC) Other Non-Current Assets (2018 - 2026) Analysis & Trends
NextCure's Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $847000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 158.23% year-over-year to $847000.0; the TTM figure through Mar 2026 stood at $847000.0 (up 158.23% YoY), while the FY2025 annual figure was $546000.0, up 64.46% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $847000.0, up from $546000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $3.3 million in Q4 2022, with the low at $328000.0 in Q1 2025.
- The 5-year median for Other Non-Current Assets is $1.9 million (2024), against an average of $1.6 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets soared 465.86% in 2022, then tumbled 82.53% in 2025.
- NextCure's Other Non-Current Assets stood at $3.3 million in 2022, then sank by 42.36% to $1.9 million in 2023, then plunged by 82.36% to $332000.0 in 2024, then surged by 64.46% to $546000.0 in 2025, then soared by 55.13% to $847000.0 in 2026.
- Business Quant data shows NXTC's Other Non-Current Assets at $847000.0 in Q1 2026, $546000.0 in Q4 2025, and $550000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 82,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | 550,000.00 |
| Jun 30, 2025 | 555,000.00 |
| Mar 31, 2025 | 328,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.88 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Sep 30, 2023 | 2.85 Mn |
| Jun 30, 2023 | 2.86 Mn |
| Mar 31, 2023 | 2.82 Mn |
| Dec 31, 2022 | 3.27 Mn |
| Sep 30, 2022 | 2.47 Mn |
| Jun 30, 2022 | 801,000.00 |
| Mar 31, 2022 | 574,000.00 |
| Dec 31, 2021 | 577,000.00 |
| Sep 30, 2021 | 581,000.00 |